Polymyxins are commonly used as the last resort for the treatment of MDR Acinetobacter
baumannii and Klebsiella pneumoniae nosocomial infections; however, apart from the …

Carbapenem-resistant Acinetobacter baumannii (CR-Ab) infections are associated with high
morbidity and mortality. The aim of the study was to evaluate the in-vitro activity of different …

Aims: Colistin became the primary treatment option for Acinetobacters that had developed a
high rate of resistance to carbapenems which were the first-line therapy in the past, and now …

Aims: Polymyxin-based combination therapy is often used to treat carbapenem-resistant
Acinetobacter baumannii (A. baumannii) infections. Although sulbactam is intrinsically active …

Increased use of colistin in a clinical setting had resulted in the emergence of colistin-
resistant (CoR) Acinetobacter baumannii. Combination therapy has been studied as a new …

Emerging resistance to colistin in clinical Acinetobacter baumannii isolates is of growing
concern. Since current treatment options for these strains are extremely limited, we …

Objective Nosocomial infection caused by carbapenem-resistant Acinetobacter baumannii is
a worldwide problem and treatment options remain controversial. This study investigated the …

Acinetobacter baumannii is currently classified as one of six pathogens that contribute to
increased patient mortality. Thus, exploratory studies navigating alternative treatment …

In order to provide preliminary guidance for rational antibiotic combination therapy in the
clinic, a systematic review and meta-analysis was performed to evaluate the in vitro …

The emergence of extreme drug resistant (XDR) Pseudomonas aeruginosa and
Acinetobacter baumannii represent a major problem in health care settings. Colistin is the …